Premium
Identification of the active metabolite of ticlopidine from rat in vitro metabolites
Author(s) -
Yoneda Kenji,
Iwamura Ryou,
Kishi Hiroko,
Mizukami Yoichi,
Mogami Kimiko,
Kobayashi Sei
Publication year - 2004
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0705808
Subject(s) - chemistry , metabolite , ticlopidine , active metabolite , in vivo , in vitro , platelet , chromatography , biochemistry , stereochemistry , biophysics , biology , microbiology and biotechnology , aspirin , immunology , clopidogrel
Ticlopidine is a well‐known anti‐platelet agent, but is not active by itself in vitro . We identified a metabolite with anti‐platelet activity, which was generated after incubation of 2‐oxo‐ticlopidine with phenobarbital‐induced rat liver homogenate in vitro . An active moiety (UR‐4501) was isolated by high‐performance liquid chromatography after large‐scale preparation of metabolites. The chemical structure of UR‐4501 was determined by a combination of liquid chromatography mass/mass spectrometry (LC/MS/MS) and nuclear magnetic resonance (NMR) analysis. UR‐4501 produced a concentration‐dependent inhibition (3–100 μ M ) of ADP (10 μ M )‐induced human platelet aggregation, whereas 2‐oxo‐ticlopidine (3–100 μ M ) did not elicit inhibitory responses. UR‐4501 (10–100 μ M ) strongly inhibited ADP‐ and collagen‐induced aggregation and slightly inhibited thrombin‐induced aggregation. The inhibition of rat washed platelet aggregation by UR‐4501 (100 μ M ) persisted, even after the platelets had been washed twice. These results suggest that UR‐4501 is the molecule responsible for the in vivo activities of ticlopidine.British Journal of Pharmacology (2004) 142 , 551–557. doi: 10.1038/sj.bjp.0705808